RU2750934C2 - ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ И ИНГИБИТОР АПФ - Google Patents
ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ И ИНГИБИТОР АПФ Download PDFInfo
- Publication number
- RU2750934C2 RU2750934C2 RU2018110622A RU2018110622A RU2750934C2 RU 2750934 C2 RU2750934 C2 RU 2750934C2 RU 2018110622 A RU2018110622 A RU 2018110622A RU 2018110622 A RU2018110622 A RU 2018110622A RU 2750934 C2 RU2750934 C2 RU 2750934C2
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- atorvastatin
- perindopril
- aspirin
- indapamide
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1570030 | 2015-08-27 | ||
FR1570030A FR3040303B1 (fr) | 2015-08-27 | 2015-08-27 | Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca |
PCT/FR2016/052126 WO2017032953A1 (fr) | 2015-08-27 | 2016-08-26 | COMPOSITION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE LA HMG-CoA REDUCTASE ET UN INHIBITEUR ECA |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2018110622A RU2018110622A (ru) | 2019-09-27 |
RU2018110622A3 RU2018110622A3 (ko) | 2020-01-31 |
RU2750934C2 true RU2750934C2 (ru) | 2021-07-06 |
Family
ID=54708062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018110622A RU2750934C2 (ru) | 2015-08-27 | 2016-08-26 | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ И ИНГИБИТОР АПФ |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP3340980A1 (ko) |
KR (1) | KR20180041233A (ko) |
CN (1) | CN108135882A (ko) |
BR (1) | BR112018003392A2 (ko) |
EA (1) | EA038261B1 (ko) |
FR (1) | FR3040303B1 (ko) |
GE (1) | GEP20207170B (ko) |
MA (1) | MA42696A (ko) |
MX (1) | MX2018002373A (ko) |
PH (1) | PH12018500370A1 (ko) |
RU (1) | RU2750934C2 (ko) |
SG (2) | SG10202000597UA (ko) |
TN (1) | TN2018000055A1 (ko) |
UA (1) | UA122908C2 (ko) |
WO (1) | WO2017032953A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102245273B1 (ko) * | 2019-03-15 | 2021-04-28 | 서울대학교병원 | 노르안하이드로이카리틴을 포함하는 심혈관 대사 질환의 예방 또는 치료용 조성물 |
EP3842035A1 (en) | 2019-12-23 | 2021-06-30 | KRKA, d.d., Novo mesto | Composition for the preparation of perindopril arginine granules, a method for their preparation and pharmaceutical composition comprising the granules |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5273995A (en) * | 1989-07-21 | 1993-12-28 | Warner-Lambert Company | [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof |
WO1999011260A1 (en) * | 1997-08-29 | 1999-03-11 | Pfizer Inc. | Combination therapy comprising atorvastatin and an antihypertensive agent |
WO1999047123A1 (en) * | 1998-03-18 | 1999-09-23 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a statin and aspirin |
WO2003087050A2 (fr) * | 2002-04-18 | 2003-10-23 | Les Laboratoires Servier | Sel de perindopril et les compositions pharmaceutiques qui le contiennent |
WO2004080488A2 (de) * | 2003-03-10 | 2004-09-23 | Bayer Healthcare Ag | Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase |
CN101612403A (zh) * | 2009-08-13 | 2009-12-30 | 王丽燕 | 含钙拮抗剂、ace抑制剂和他汀类药的药物组合物 |
US20100092549A1 (en) * | 2007-02-09 | 2010-04-15 | Sandra Blundell | Dosage Form Containing Two or More Active Pharmaceutical Ingredients in Different Physical Forms |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2010135524A (ru) * | 2008-01-25 | 2012-02-27 | Торрент Фармасьютикалз Лтд. (In) | Фармацевтические комбинации |
CN101791297B (zh) * | 2010-02-10 | 2012-03-28 | 中国药科大学 | 阿托伐他汀钙口崩片及其制备方法 |
-
2015
- 2015-08-27 FR FR1570030A patent/FR3040303B1/fr not_active Expired - Fee Related
-
2016
- 2016-08-26 WO PCT/FR2016/052126 patent/WO2017032953A1/fr active Application Filing
- 2016-08-26 SG SG10202000597UA patent/SG10202000597UA/en unknown
- 2016-08-26 MX MX2018002373A patent/MX2018002373A/es unknown
- 2016-08-26 EA EA201890591A patent/EA038261B1/ru unknown
- 2016-08-26 KR KR1020187008533A patent/KR20180041233A/ko not_active Application Discontinuation
- 2016-08-26 TN TNP/2018/000055A patent/TN2018000055A1/en unknown
- 2016-08-26 UA UAA201802860A patent/UA122908C2/uk unknown
- 2016-08-26 RU RU2018110622A patent/RU2750934C2/ru active
- 2016-08-26 BR BR112018003392-8A patent/BR112018003392A2/pt not_active IP Right Cessation
- 2016-08-26 CN CN201680058043.2A patent/CN108135882A/zh active Pending
- 2016-08-26 SG SG11201801382UA patent/SG11201801382UA/en unknown
- 2016-08-26 GE GEAP201614734A patent/GEP20207170B/en unknown
- 2016-08-26 MA MA042696A patent/MA42696A/fr unknown
- 2016-08-26 EP EP16763927.7A patent/EP3340980A1/fr not_active Withdrawn
-
2018
- 2018-02-19 PH PH12018500370A patent/PH12018500370A1/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5273995A (en) * | 1989-07-21 | 1993-12-28 | Warner-Lambert Company | [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof |
WO1999011260A1 (en) * | 1997-08-29 | 1999-03-11 | Pfizer Inc. | Combination therapy comprising atorvastatin and an antihypertensive agent |
WO1999047123A1 (en) * | 1998-03-18 | 1999-09-23 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a statin and aspirin |
WO2003087050A2 (fr) * | 2002-04-18 | 2003-10-23 | Les Laboratoires Servier | Sel de perindopril et les compositions pharmaceutiques qui le contiennent |
WO2004080488A2 (de) * | 2003-03-10 | 2004-09-23 | Bayer Healthcare Ag | Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase |
US20100092549A1 (en) * | 2007-02-09 | 2010-04-15 | Sandra Blundell | Dosage Form Containing Two or More Active Pharmaceutical Ingredients in Different Physical Forms |
CN101612403A (zh) * | 2009-08-13 | 2009-12-30 | 王丽燕 | 含钙拮抗剂、ace抑制剂和他汀类药的药物组合物 |
Non-Patent Citations (3)
Title |
---|
Florence A. T., Siepmann J. (ed.). Modern Pharmaceutics Volume 1: Basic Principles and Systems. - CRC Press, 2009. * |
Karpov Yu.A. Perindopril arginine: a new salt of an angiotensin converting enzyme inhibitor expands the possibilities of application // Cardiovascular therapy and prevention. - 2008. - T. 7. - N. 6 . * |
Карпов Ю. А. Периндоприла аргинин: новая соль ингибитора ангиотензин-превращающего фермента расширяет возможности применения //Кардиоваскулярная терапия и профилактика. - 2008. - Т. 7. - N. 6.. * |
Also Published As
Publication number | Publication date |
---|---|
FR3040303A1 (fr) | 2017-03-03 |
BR112018003392A2 (pt) | 2018-09-25 |
UA122908C2 (uk) | 2021-01-20 |
RU2018110622A (ru) | 2019-09-27 |
EA038261B1 (ru) | 2021-07-30 |
MX2018002373A (es) | 2018-07-06 |
WO2017032953A1 (fr) | 2017-03-02 |
PH12018500370A1 (en) | 2018-08-29 |
TN2018000055A1 (en) | 2019-07-08 |
EP3340980A1 (fr) | 2018-07-04 |
CN108135882A (zh) | 2018-06-08 |
MA42696A (fr) | 2018-07-04 |
GEP20207170B (en) | 2020-10-12 |
FR3040303B1 (fr) | 2019-04-05 |
SG10202000597UA (en) | 2020-03-30 |
RU2018110622A3 (ko) | 2020-01-31 |
SG11201801382UA (en) | 2018-03-28 |
EA201890591A1 (ru) | 2018-09-28 |
KR20180041233A (ko) | 2018-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2273985T3 (en) | Capsule for the prevention of cardiovascular diseases | |
US8642083B2 (en) | Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors | |
KR100955669B1 (ko) | HMGCoA 환원효소 저해제와 아스피린을 포함하는 복합제제 및 그의 제조방법 | |
RU2450804C2 (ru) | КОМБИНИРОВАННОЕ ФАРМАЦЕВТИЧЕСКОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО С КОНТРОЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩЕЕ ДИГИДРОПИРИДИНОВЫЕ БЛОКАТОРЫ КАЛЬЦИЕВЫХ КАНАЛОВ И ИНГИБИТОРЫ HMG-CоА-РЕДУКТАЗЫ | |
ES2690741T3 (es) | Composición farmacéutica estable para la aterosclerosis | |
HUT62488A (en) | Process for producing orally administrable pharmaceutical compositions comprising coagulation and platelet function inhibiting active ingredients in small dose | |
CA2531279A1 (en) | Treatment and preventi0n of cardiovascular events | |
EP1581194A2 (en) | Multilayered tablet containing pravastatin and aspirin and method | |
US20120045505A1 (en) | Fixed dose drug combination formulations | |
JP2009511191A (ja) | 経口投与剤組合せ型医薬パッケージ法 | |
RU2750934C2 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ И ИНГИБИТОР АПФ | |
RU2491070C2 (ru) | Фармацевтическая композиция для профилактики и лечения сердечно-сосудистых заболеваний | |
RU2756320C2 (ru) | Фармацевтическая композиция, содержащая бета-блокатор, ингибитор превращающего фермента и гипотензивное средство или нпвс | |
JP2011500558A (ja) | HMG−CoA還元酵素抑制剤と胆汁酸を含むC型肝炎治療用薬学組成物 | |
KR101072600B1 (ko) | 플루바스타틴을 포함하는 안정한 약제학적 조성물 및 그의 제조방법 | |
CN101590236A (zh) | 含有钙拮抗剂、他汀类药物的组合物及其用途 | |
HU211938A9 (hu) | Koagulációt és vérlemezke-működést gátló hatóanyagokat kis dózisban tartalmazó, orális adagolású gyógyszerkészítmények Az átmeneti oltalom a 2-24. igénypontokra vonatkozik. | |
MXPA06000823A (es) | Tratamiento y prevencion de eventos cardiovasculares |